AstraZeneca buys into cardio again; pays $310mm for Omthera Pharmaceuticals
Executive Summary
For the second time in two months, AstraZeneca PLC has boosted its cardiovascular drugs business, this time through the purchase of Omthera Pharmaceuticals Inc., a five-year-old public specialty pharma company developing therapies for lipid disorders. AZ paid $310mm up front ($12.70 per share, an 80% premium), and sweetened the offer with contingent value rights (CVRs) of up to $4.70 per share, or an additional $120mm in total if all CVR milestones related to Omthera's lead candidate Epanova are met. The Big Pharma also takes on Omthera’s cash balances of about $63mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice